Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Collaboration
Eyenovia and Senju Pharmaceutical Sign Collaboration for Chronic Dry Eye Treatment
Details : both companies intend to work to develop Senju’s corneal epithelial candidate, SJP-0035, for use with Eyenovia’s Optejet dispensing technology, as a potential treatment for chronic dry eye disease.
Brand Name : SJP-0035
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 23, 2024
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?